Method of combination therapy using an anti-C-Met antibody
A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.
1. A method for treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need of treatment of the cancer;
wherein the cancer is associated with c-Met activity or overexpression of c-Met; and
wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region comprising (a) a complementarity determining region-H1 (CDR-H1) having an amino acid sequence consisting of SEQ ID NO: 1, (b) a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 2, and (c) a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 3; and
a light chain variable region comprising: (a) a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 10 or 71, (b) a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 11, and (c) a CDR-L3 having an amino acid sequence comprising SEQ ID NO: 13, 14, 15, or 16.
2. The method of claim 1 , wherein the anti-c-Met antibody or an antigen-binding fragment thereof, and the at least one of lapatinib, regorafenib, vemurafenib, or combination thereof, are administered simultaneously or sequentially in any order.
3. The method of claim 1 , wherein the light chain variable region comprises
CDR-L1 having an amino acid sequence of SEQ ID NO: 10, CDR-L2 having an amino acid sequence of SEQ ID NO: 11, and CDR-L3 having an amino acid sequence of SEQ ID NO: 13, 14, 15, or 16; or
CDR-L1 having an amino acid sequence of SEQ ID NO: 71, CDR-L2 having an amino acid sequence of SEQ ID NO: 11, and CDR-L3 having an amino acid sequence of SEQ ID NO: 13.
4. The method of claim 1 , wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises the heavy chain variable region has an amino acid sequence of SEQ ID NO: 17, and the light chain variable region has an amino acid sequence of SEQ ID NO: 74, 18, 19, 20, 21, or 72.
5. The method of claim 1 , wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises:
a heavy chain comprising an amino acid sequence from 18 th to 462 nd of SEQ ID NO: 62, an amino acid sequence from 18 th to 461 st of SEQ ID NO: 64, or amino acid sequence from 18 th to 460 th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence from 21 st to 220 th of SEQ ID NO: 68;
a heavy chain comprising an amino acid sequence from 18 th to 462 nd of SEQ ID NO: 62, an amino acid sequence from 18 th to 461 st of SEQ ID NO: 64, or amino acid sequence from 18 th to 460 th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence from 21 st to 220 th of SEQ ID NO: 70; or
a heavy chain comprising an amino acid sequence from 18 th to 462 nd of SEQ ID NO: 62, an amino acid sequence from 18 th to 461 st of SEQ ID NO: 64, or amino acid sequence from 18 th to 460 th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence of SEQ ID NO: 73.
6. The method for treatment of a cancer of claim 1 , wherein the cancer is breast cancer, colon cancer, lung cancer, kidney cancer, or gastric cancer.